MX2016005017A - Metodos para el tratamiento de condiciones asociadas con la activacion del complemento dependiente de masp-2. - Google Patents

Metodos para el tratamiento de condiciones asociadas con la activacion del complemento dependiente de masp-2.

Info

Publication number
MX2016005017A
MX2016005017A MX2016005017A MX2016005017A MX2016005017A MX 2016005017 A MX2016005017 A MX 2016005017A MX 2016005017 A MX2016005017 A MX 2016005017A MX 2016005017 A MX2016005017 A MX 2016005017A MX 2016005017 A MX2016005017 A MX 2016005017A
Authority
MX
Mexico
Prior art keywords
masp
activation
dependent complement
methods
dependent
Prior art date
Application number
MX2016005017A
Other languages
English (en)
Other versions
MX389699B (es
Inventor
Gregory A Demopulos
Thomas Dudler
Schwaeble Hans-Wilhelm
Original Assignee
Omeros Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Omeros Corp filed Critical Omeros Corp
Publication of MX2016005017A publication Critical patent/MX2016005017A/es
Publication of MX389699B publication Critical patent/MX389699B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Photoreceptors In Electrophotography (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

En un aspecto, la invención proporciona métodos de inhibición de los efectos de la activación del complemento dependiente de MASP-2 en un sujeto vivo que sufre de, o en riesgo de desarrollar una microangiopatía trombótica (TMA). Los métodos comprenden el paso de administrar, a un sujeto en necesidades del mismo, una cantidad de un agente inhibidor de MASP-2 efectiva para inhibir la activación del complemento dependiente de MASP-2. En algunas modalidades, el agente inhibidor de MASP-2 inhibe la lesión celular asociada a MASP-2 mediada por activación de la vía alternativa del complemento, mientras que deja la Vía clásica (dependiente de Clq) del a clásica del sistema inmune intacto.
MX2016005017A 2013-10-17 2014-10-17 Composiciones que comprenden anticuerpos inhibidores de masp-2 para usarse en el tratamiento de post-trasplante de celulas madre de microangiopatía trombótica (tma). MX389699B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361892283P 2013-10-17 2013-10-17
US201462020845P 2014-07-03 2014-07-03
PCT/US2014/061236 WO2015058143A1 (en) 2013-10-17 2014-10-17 Methods for treating conditions associated with masp-2 dependent complement activation

Publications (2)

Publication Number Publication Date
MX2016005017A true MX2016005017A (es) 2016-11-07
MX389699B MX389699B (es) 2025-03-20

Family

ID=52828769

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016005017A MX389699B (es) 2013-10-17 2014-10-17 Composiciones que comprenden anticuerpos inhibidores de masp-2 para usarse en el tratamiento de post-trasplante de celulas madre de microangiopatía trombótica (tma).
MX2021008044A MX2021008044A (es) 2013-10-17 2016-04-18 Metodos para el tratamiento de condiciones asociadas con la activacion del complemento dependiente de masp-2.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021008044A MX2021008044A (es) 2013-10-17 2016-04-18 Metodos para el tratamiento de condiciones asociadas con la activacion del complemento dependiente de masp-2.

Country Status (25)

Country Link
US (3) US20150166675A1 (es)
EP (2) EP3057993B1 (es)
JP (3) JP2016539919A (es)
KR (3) KR20160062186A (es)
CN (2) CN111588855A (es)
AU (2) AU2014337047B2 (es)
BR (1) BR112016008409B1 (es)
CA (1) CA2926385A1 (es)
CL (2) CL2016000908A1 (es)
CY (1) CY1123776T1 (es)
DK (1) DK3057993T3 (es)
ES (1) ES2829913T3 (es)
HR (1) HRP20201733T1 (es)
HU (1) HUE051746T2 (es)
IL (2) IL283373B2 (es)
LT (1) LT3057993T (es)
MX (2) MX389699B (es)
NZ (2) NZ719476A (es)
PL (1) PL3057993T3 (es)
PT (1) PT3057993T (es)
RS (1) RS61351B1 (es)
RU (1) RU2718850C2 (es)
SI (1) SI3057993T1 (es)
SM (1) SMT202000659T1 (es)
WO (1) WO2015058143A1 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8951522B2 (en) 2011-04-08 2015-02-10 University Of Leicester Methods for treating conditions associated with MASP-2 dependent complement activation
US8840893B2 (en) 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US9644035B2 (en) 2011-04-08 2017-05-09 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
LT3057993T (lt) 2013-10-17 2020-11-25 Omeros Corporation Gydymo būdai būklių, susijusių su nuo masp-2 priklausomu komplemento aktyvinimu
US20170137537A1 (en) * 2015-11-09 2017-05-18 Omeros Corporation Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
CA3010593C (en) * 2016-01-05 2024-02-13 University Of Leicester Methods for inhibiting fibrosis in a subject in need thereof
CN109152834A (zh) * 2016-03-31 2019-01-04 奥默罗斯公司 抑制有需要的受试者的血管发生的方法
JOP20170170B1 (ar) * 2016-08-31 2022-09-15 Omeros Corp صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق
JOP20190068A1 (ar) * 2016-10-13 2019-04-01 Omeros Corp طرق لتقليل البول البروتيني في خاضع بشري يعاني من الاعتلال الكلوي a الناتج عن الجلوبيولين المناعي
TWI818919B (zh) 2017-08-15 2023-10-21 美商歐米諾斯公司 用於治療和／ 或預防與造血幹細胞移植有關的移植物抗宿主病和／ 或瀰漫性肺泡出血和／ 或靜脈閉塞性病的方法
EP3672994A4 (en) * 2017-08-25 2021-06-02 Omeros Corporation HIGHLY CONCENTRATED LOW VISCOSITY MASP-2 INHIBITIVE ANTIBODY FORMULATIONS, KITS, AND METHODS FOR TREATING PEOPLE WITH ATYPICAL HEMOLYTIC SYNDROME
CN108171772B (zh) * 2017-12-28 2021-11-19 中国地质调查局西安地质调查中心 利用mapGIS、CJKCOOR_Ver和DELF3D提取河流边界的方法
KR20210016545A (ko) 2018-05-29 2021-02-16 오메로스 코포레이션 Masp-2 억제제 및 사용 방법
KR20210024003A (ko) * 2018-06-22 2021-03-04 오메로스 코포레이션 다양한 혈전성 질환 및 장애의 치료를 위한 masp-2 억제 조성물 및 방법
BR112021011107A2 (pt) * 2018-12-13 2021-12-14 Argenx Bvba Anticorpos para o fator de complemento humano c2b e métodos de uso
CN111134250A (zh) * 2019-12-03 2020-05-12 海南大学 一种草地贪夜蛾幼虫食用人工饲料的配方和制作方法
EP4069678A1 (en) 2019-12-04 2022-10-12 Omeros Corporation Masp-2 inhibitors and methods of use
WO2021113682A1 (en) 2019-12-04 2021-06-10 Omeros Corporation Masp-2 inhibitors and methods of use
EP4069676A1 (en) 2019-12-04 2022-10-12 Omeros Corporation Masp-2 inhibitors and methods of use
WO2021113686A1 (en) 2019-12-04 2021-06-10 Omeros Corporation Masp-2 inhibitors and methods of use
US12383547B2 (en) 2020-07-01 2025-08-12 Vanderbilt University Methods of treatment for a kidney disease
CN115215937B (zh) * 2021-04-15 2023-05-26 上海麦济生物技术有限公司 抗人masp-2抗体及其制备方法和应用
CN115300608B (zh) * 2021-05-06 2023-06-02 四川大学 一种利用甘露糖结合凝集素阻断新冠病毒感染的方法
US20230265215A1 (en) 2021-12-10 2023-08-24 Omeros Corporation Therapeutic antibodies that bind to the serine protease domain of masp-2 and uses thereof
JP2025541737A (ja) 2022-11-30 2025-12-23 オメロス コーポレーション Ｍａｓｐ－２阻害物質としての縮合ピリミジン
WO2025076476A2 (en) 2023-10-06 2025-04-10 Omeros Corporation Masp-2 inhibitors and methods of use
CN119143861B (zh) * 2024-11-19 2025-01-24 四川大学 一种甘露聚糖结合凝集素改造蛋白ppg-rep-MBL、DNA分子、表达载体、宿主细胞，以及用途

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4394370A (en) 1981-09-21 1983-07-19 Jefferies Steven R Bone graft material for osseous defects and method of making same
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4526909A (en) 1984-01-09 1985-07-02 Regents Of The University Of California Polymethylmethacrylate delivery system for bone morphogenetic protein
US4563489A (en) 1984-02-10 1986-01-07 University Of California Biodegradable organic polymer delivery system for bone morphogenetic protein
JPH0662679B2 (ja) 1985-06-21 1994-08-17 新田ゼラチン株式会社 組織親和性コラ−ゲンとその製法
US5453566A (en) 1986-03-28 1995-09-26 Calgene, Inc. Antisense regulation of gene expression in plant/cells
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
ATE115999T1 (de) 1987-12-15 1995-01-15 Gene Shears Pty Ltd Ribozyme.
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8822492D0 (en) 1988-09-24 1988-10-26 Considine J Apparatus for removing tumours from hollow organs of body
US5211657A (en) 1988-11-07 1993-05-18 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
SG46445A1 (en) 1990-01-26 1998-02-20 Immunomedics Inc Vaccines against cancer and infectious diseases
JP3218637B2 (ja) 1990-07-26 2001-10-15 大正製薬株式会社 安定なリポソーム水懸濁液
US5789573A (en) 1990-08-14 1998-08-04 Isis Pharmaceuticals, Inc. Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2
JP2958076B2 (ja) 1990-08-27 1999-10-06 株式会社ビタミン研究所 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
IL108367A0 (en) 1993-01-27 1994-04-12 Hektoen Inst For Medical Resea Antisense polynzcleotide inhibition of human growth factor-sensitive cancer cells
US5801154A (en) 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
US5856121A (en) 1994-02-24 1999-01-05 Case Western Reserve University Growth arrest homebox gene
US5741516A (en) 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
JPH10510540A (ja) 1994-12-12 1998-10-13 オメロス メディカル システムズ，インコーポレーテッド 灌注用溶液並びに疼痛、炎症及びけいれんの抑制法
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5738868A (en) 1995-07-18 1998-04-14 Lipogenics Ltd. Liposome compositions and kits therefor
US5739119A (en) 1996-11-15 1998-04-14 Galli; Rachel L. Antisense oligonucleotides specific for the muscarinic type 2 acetylcholine receptor MRNA
EP1200127B1 (en) 1999-07-21 2008-06-25 Omeros Corporation Solutions and methods for inhibition of pain, inflammation and cartilage degradation
US6649592B1 (en) 2000-01-14 2003-11-18 Science & Technology Corporation @ Unm Peptide inhibitors of LFA-1/ICAM-1 interaction
SG98393A1 (en) 2000-05-19 2003-09-19 Inst Materials Research & Eng Injectable drug delivery systems with cyclodextrin-polymer based hydrogels
WO2003063799A2 (en) 2002-02-01 2003-08-07 Omeros Corporation Compositions and methods for systemic inhibition of cartilage degradation
JP4723244B2 (ja) 2002-07-19 2011-07-13 オメロス コーポレイション 生分解性トリブロックコポリマー、その合成方法、ならびにそれから作製されるヒドロゲルおよび生体材料
ES2541134T3 (es) * 2003-05-12 2015-07-16 Helion Biotech Aps Anticuerpos de MASP-2
US20050169921A1 (en) 2004-02-03 2005-08-04 Leonard Bell Method of treating hemolytic disease
US8951522B2 (en) * 2011-04-08 2015-02-10 University Of Leicester Methods for treating conditions associated with MASP-2 dependent complement activation
US7919094B2 (en) 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US20130266559A1 (en) * 2004-06-10 2013-10-10 University Of Leicester Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
PL2465534T3 (pl) * 2004-06-10 2017-08-31 Omeros Corporation Sposoby leczenia stanów związanych z aktywacją dopełniacza zależną od masp-2
US8840893B2 (en) 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
HUE061548T2 (hu) * 2008-11-10 2023-07-28 Alexion Pharma Inc Komplementtel összefüggõ rendellenességek kezelésére szolgáló eljárások és készítmények
US20120282285A1 (en) 2009-07-17 2012-11-08 Rigshospitalet Masp isoforms as inhibitors of complement activation
AU2010306581B2 (en) * 2009-10-16 2015-03-19 Omeros Corporation Methods for treating disseminated intravascular coagulation by inhibiting MASP-2 dependent complement activation
NZ602219A (en) 2010-03-01 2014-10-31 Alexion Pharma Inc Methods and compositions for treating degos’ disease
US20150166676A1 (en) 2011-04-08 2015-06-18 Omeros Corporation Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
US9644035B2 (en) * 2011-04-08 2017-05-09 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
EP3725811A3 (en) * 2011-05-04 2021-01-27 Omeros Corporation Compositions for inhibiting masp-2 dependent complement activation
JP2013030593A (ja) 2011-07-28 2013-02-07 J Devices:Kk 半導体装置、該半導体装置を垂直に積層した半導体モジュール構造及びその製造方法
KR20200015952A (ko) 2012-06-18 2020-02-13 오메로스 코포레이션 다양한 질환 및 장애의 치료를 위해 masp-1 및/또는 masp-2 및/또는 masp-3를 억제하는 조성물 및 방법
CN104870475B (zh) 2012-10-25 2019-11-08 美国比奥维拉迪维股份有限公司 抗补体C1s抗体和其用途
JP6654137B2 (ja) 2013-09-16 2020-02-26 チルドレンズ ホスピタル メディカル センター Ｈｓｃｔ関連血栓性微小血管症の治療のための組成物及び方法
LT3057993T (lt) 2013-10-17 2020-11-25 Omeros Corporation Gydymo būdai būklių, susijusių su nuo masp-2 priklausomu komplemento aktyvinimu
US20170137537A1 (en) 2015-11-09 2017-05-18 Omeros Corporation Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation

Also Published As

Publication number Publication date
BR112016008409B1 (pt) 2021-06-15
MX2021008044A (es) 2021-10-13
US11525011B2 (en) 2022-12-13
PL3057993T3 (pl) 2021-02-08
JP2016539919A (ja) 2016-12-22
AU2014337047A1 (en) 2016-05-19
KR102677379B1 (ko) 2024-06-24
AU2020203748B2 (en) 2022-08-04
US20150166675A1 (en) 2015-06-18
WO2015058143A1 (en) 2015-04-23
HRP20201733T1 (hr) 2021-02-05
IL283373A (en) 2021-07-29
RU2016118769A3 (es) 2018-11-21
BR112016008409A2 (pt) 2017-10-03
DK3057993T3 (en) 2020-11-16
EP3057993B1 (en) 2020-08-12
IL283373B2 (en) 2024-08-01
EP3750919A1 (en) 2020-12-16
NZ757986A (en) 2022-07-29
KR20220053057A (ko) 2022-04-28
JP7397037B2 (ja) 2023-12-12
CN105683219B (zh) 2020-07-14
IL245115A0 (en) 2016-06-30
HUE051746T2 (hu) 2021-03-29
RU2016118769A (ru) 2017-11-22
CL2018001557A1 (es) 2018-07-20
US20200157244A1 (en) 2020-05-21
CL2016000908A1 (es) 2016-12-02
CA2926385A1 (en) 2015-04-23
SMT202000659T1 (it) 2021-01-05
KR20160062186A (ko) 2016-06-01
CN105683219A (zh) 2016-06-15
CY1123776T1 (el) 2022-03-24
CN111588855A (zh) 2020-08-28
MX389699B (es) 2025-03-20
RU2718850C2 (ru) 2020-04-15
JP6953498B2 (ja) 2021-10-27
KR20240101700A (ko) 2024-07-02
RU2020111211A (ru) 2021-11-08
US20240124611A1 (en) 2024-04-18
JP2020037568A (ja) 2020-03-12
RS61351B1 (sr) 2021-02-26
PT3057993T (pt) 2020-11-19
AU2020203748A1 (en) 2020-06-25
EP3057993A1 (en) 2016-08-24
ES2829913T3 (es) 2021-06-02
EP3057993A4 (en) 2017-09-13
SI3057993T1 (sl) 2021-03-31
IL245115B (en) 2022-05-01
NZ719476A (en) 2022-07-29
JP2022000467A (ja) 2022-01-04
IL283373B1 (en) 2024-04-01
LT3057993T (lt) 2020-11-25
KR102744762B1 (ko) 2024-12-20
AU2014337047B2 (en) 2020-03-12

Similar Documents

Publication Publication Date Title
MX2016005017A (es) Metodos para el tratamiento de condiciones asociadas con la activacion del complemento dependiente de masp-2.
CL2018001258A1 (es) Métodos para tratar las condiciones asociadas con la activación del complemento dependiente de masp-2
CY1123229T1 (el) Χρηση των κανναβινοειδων στη θεραπεια των ατονικων κρισεων στο συνδρομο lennox-gastaut
MX378686B (es) Composiciones que comprenden cepas bacterianas.
MX375706B (es) Compuestos de inhibidor de autotaxina.
CL2016000055A1 (es) Métodos para tratar o prevenir afecciones oftalmológicas
MX2015010724A (es) Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer.
CR20150376A (es) Compuestos sustituidos de pirrolopirimidina, compuestos de los mismos y metodos de tratamiento con los mismos
BR112017006664A2 (pt) terapias de combinação
CL2016001082A1 (es) Proceso para la síntesis de un inhibidor de indolamina 2,3-dioxigenasa
CL2018000597A1 (es) Métodos para tratar enfermedades inflamatorias
MX388380B (es) Composiciones para usarse en el incremento de los niveles de glóbulos rojos y el tratamiento de enfermedad de células falciformes.
CL2017000416A1 (es) Métodos para tratar el mieloma múltiple con compuestos inmunomoduladores en combinación con anticuerpos
SG10201808940WA (en) Nox inhibitor and nfкb inhibitor containing methoxyflavone
MX2015016100A (es) Inhibidores de criopirina para prevenir y tratar la inflamacion.
CL2016000326A1 (es) Composiciones y método para tratar condiciones asociadas con el complemento
CR20170259A (es) Terapias de envenenamiento y composiciones farmacéuticas, sistemas y equipos relacionados
CL2016001076A1 (es) (aza) piridopirazolopirimidinonas e indazolopirimidinonas como inhibidores de fibrinolosis.
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
CR20150496A (es) Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a
MX2017010654A (es) Oxabicicloheptanos y oxabicicloheptenos para el tratamiento de trastornos depresivos y de estres.
BR112016012248A2 (pt) método de tratamento de nefropatia
CL2017002967A1 (es) Beta-caseinas a2 y capacidad antioxidante.
MX374340B (es) Administracion de farmacos antiinflamatorios no esteroidales y composiciones, metodos y sistemas relacionados.
BR112016014099A2 (pt) método de tratamento de feridas